学科与关键词
关键词
NSCLCExon 20 insertionAmivantamab
- Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysisZhou, C.; Tang, K.; Liu, B.; Kim, S-W.; Kitazono, S.; Ono, A.; Thiagarajan, M.; Hung, J-Y.; Boyer, M.; Xie, J.; Bhattacharya, A.; Baig, M.; Agrawal, T.; Knoblauch, R. E.; Cho, B. C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung AdenocarcinomaPeng, K.; Wang, H.; Gao, Y.; Li, X.; Gao, Q.; Zhang, S.; Yang, J.
- Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysisLu, S.; Cho, B. C.; Lee, J-S.; Lee, S-H.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-C.; Yang, J. C-H.; Yoshioka, H.; Xia, K.; Martinez, M.; Bauml, J. M.; Sethi, S.; Hayashi, H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
